{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:49:19Z","timestamp":1792100959349,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":286,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,4]]},"abstract":"<jats:p>We report our experience with the combination of anti\u2010thymocyte globulin (ATGAM) and tacrolimus in the treatment of 20 patients with steroid refractory and dependent acute graft\u2010versus\u2010host disease (GVHD) transplanted between August 1996 and February 2000. All patients received cyclosporine\u2010based GVHD prophylaxis. Thirteen patients developed a maximum of grade IV, five grade III and two grade II acute GVHD, with 15 patients being refractory to steroids and five dependent on steroids. Patients were treated with ATGAM (15\u2003mg\/kg for 5\u2003d) and tacrolimus (0\u00b7025\u20130\u00b71\u2003mg\/kg\/d) in addition to continuation of their high\u2010dose steroids and cessation of their cyclosporine. Within 28\u2003d of treatment, we observed eight complete responses (CR), six partial responses (PR) and six with no response. Overall response (CR\u2003+\u2003PR) was predicted by GVHD severity. Infectious complications occurred in 80% of patients. The median survival was 86\u00b75\u2003d (range, 21\u20131081\u2003d) with 35% of patients remaining alive. Survival following combination therapy was significantly more likely in men (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001), skin\u2010only GVHD (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7027), less severe GVHD (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7048), and in responders to tacrolimus and ATGAM (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001). In conclusion, concurrent introduction of ATGAM and tacrolimus is a promising therapeutic combination for GVHD refractory to steroids and cyclosporine.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02741.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:33:10Z","timestamp":1047364390000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Combination therapy with tacrolimus and anti\u2010thymocyte globulin for the treatment of steroid\u2010resistant acute graft\u2010versus\u2010host disease developing during cyclosporine prophylaxis"],"prefix":"10.1111","volume":"113","author":[{"given":"S.","family":"Durrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1320.1320"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1342.1342"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701281"},{"key":"e_1_2_5_5_1","first-page":"1","article-title":"Management of acute graft\u2010versus\u2010host disease","volume":"6","author":"Deeg H.J.","year":"1990","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)00461-4"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830110102"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050310"},{"key":"e_1_2_5_9_1","first-page":"115","volume-title":"Clinical Transplants","author":"Fung J.J.","year":"1991"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_5_11_1","first-page":"891","article-title":"Treatment of steroid\u2010resistant graft\u2010versus\u2010host disease after allogeneic bone marrow transplantation with anti\u2010CD3\/TCR monoclonal antibodies","volume":"15","author":"Hebart H.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_12_1","first-page":"563","article-title":"Treatment of steroid\u2010resistant acute graft\u2010versus\u2010host disease with an anti\u2010IL\u20102\u2010receptor monoclonal antibody (BT 563) in children who received T cell\u2010depleted, partially matched, related bone marrow transplants","volume":"13","author":"Herbelin C.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91621-0"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199408270-00008"},{"key":"e_1_2_5_15_1","first-page":"561a","article-title":"Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporine in allogeneic bone marrow transplantation","volume":"90","author":"Hiraoka A.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701331"},{"key":"e_1_2_5_17_1","first-page":"885","article-title":"FK506 treatment of graft\u2010versus\u2010host disease developing or exacerbating during prophylaxis and therapy with cyclosporine and\/or other immunosuppressants. Japanese FK506 BMT Study Group","volume":"15","author":"Kanamaru A.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.44.3.780-782.2000","article-title":"Efficacy of SCH56592 in a rabbit model of invasive aspergillosis","volume":"44","author":"Kirkpatrick W.R.","year":"2000","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_5_19_1","first-page":"895","article-title":"FK506 (tacrolimus) in the treatment of steroid\u2010resistant acute graft\u2010versus\u2010host disease in children undergoing bone marrow transplantation","volume":"15","author":"Koehler M.T.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_20_1","first-page":"152a","article-title":"Poor outcome in steroid refractory GVHD with ATG treatment","volume":"94","author":"Margolis J.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.8.1464.1464"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.8.1821.1821"},{"key":"e_1_2_5_23_1","first-page":"3228","article-title":"Phase II study of FK 506 for allogeneic bone marrow transplantation","volume":"23","author":"Masaoka T.","year":"1991","journal-title":"Transplant Proceedings"},{"key":"e_1_2_5_24_1","first-page":"2062","article-title":"Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporinee for prophylaxis of acute graft\u2010versus\u2010host gisease after marrow transplantation from unrelated donors","volume":"96","author":"Nash R.A.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700716"},{"key":"e_1_2_5_26_1","first-page":"153a","article-title":"Acute graft\u2010versus\u2010host disease after allogeneic blood stem cell transplantation: factors determining treatment failure and survival","volume":"94","author":"Pavletic S.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.83"},{"key":"e_1_2_5_28_1","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft\u2010versus\u2010host disease prophylaxis after HLA\u2010identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn V.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.4.1094.1094"},{"key":"e_1_2_5_30_1","first-page":"77","article-title":"Acute graft\u2010versus\u2010host disease following unrelated donor marrow transplantation: failure of conventional therapy","volume":"10","author":"Roy J.","year":"1992","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141201"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1729.1729"},{"key":"e_1_2_5_33_1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood.V80.2.560.560","article-title":"Long\u2010term follow\u2010up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft\u2010versus\u2010host disease in patients administered HLA\u2010identical marrow grafts for leukemia","volume":"80","author":"Storb R.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood.V83.9.2749.2749","article-title":"Long\u2010term follow\u2010up of a randomized trial of graft\u2010versus\u2010host disease prevention by methotrexate\/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia","volume":"83","author":"Storb R.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_35_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/clinchem\/42.2.279","article-title":"Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography\u2010electrospray tandem mass spectrometry","volume":"42","author":"Taylor P.J.","year":"1996","journal-title":"Clinical Chemistry"},{"key":"e_1_2_5_36_1","first-page":"2288","article-title":"Early treatment of acute graft\u2010versus\u2010host disease with high\u2010 or low\u2010 dose 6\u2010methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation","volume":"92","author":"Van Lint M.T.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331603"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.4.1024.1024"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02741.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02741.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02741.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:54:33Z","timestamp":1697536473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02741.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02741.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02741.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}